CRTX Key Statistics, Chart & Performance
The current stock price of CRTX is 1.95 USD. In the past month the price decreased by -12.16%. In the past year, price decreased by -96.55%.
CRTX Technical Analysis
CRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CRTX. The financial health of CRTX is average, but there are quite some concerns on its profitability.
CRTX Financial Highlights
Over the last trailing twelve months CRTX reported a non-GAAP Earnings per Share(EPS) of -2.97. The EPS decreased by -6.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -76.21% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CRTX Forecast & Estimates
11 analysts have analysed CRTX and the average price target is 22.7 USD. This implies a price increase of 1063.85% is expected in the next year compared to the current price of 1.95.
CRTX Ownership
About CRTX
Company Profile
Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2019-05-09. The company’s pipeline includes a precision bone growth molecule and drug-targeting platform to treat rare skeletal diseases, bone cancer, and injury, in addition to small molecule therapeutics targeting the infectious pathogen P. gingivalis’ role in degenerative disease progression, including for indications such as periodontal disease, oral potentially malignant disorders, and Alzheimer’s disease, among others. Its drug-targeting platform allows the Company to take small molecules, peptides, or large molecules and deliver them directly to the site of disease or injury. The firm's drug candidate, COR388, is an orally administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer's disease. Its COR588 is a second-generation small-molecule lysine-gingipain inhibitor.
Company Info
CORTEXYME INC
269 East Grand Ave
South San Francisco CALIFORNIA 94080 US
CEO: Casey C. Lynch
Employees: 55
Phone: 14159105717.0
CORTEXYME INC / CRTX FAQ
What does CORTEXYME INC do?
Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2019-05-09. The company’s pipeline includes a precision bone growth molecule and drug-targeting platform to treat rare skeletal diseases, bone cancer, and injury, in addition to small molecule therapeutics targeting the infectious pathogen P. gingivalis’ role in degenerative disease progression, including for indications such as periodontal disease, oral potentially malignant disorders, and Alzheimer’s disease, among others. Its drug-targeting platform allows the Company to take small molecules, peptides, or large molecules and deliver them directly to the site of disease or injury. The firm's drug candidate, COR388, is an orally administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer's disease. Its COR588 is a second-generation small-molecule lysine-gingipain inhibitor.
What is the stock price of CORTEXYME INC today?
The current stock price of CRTX is 1.95 USD. The price increased by 2.63% in the last trading session.
Does CRTX stock pay dividends?
CRTX does not pay a dividend.
What is the ChartMill rating of CORTEXYME INC stock?
CRTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists CRTX stock?
CRTX stock is listed on the Nasdaq exchange.
How is the valuation of CORTEXYME INC (CRTX) based on its PE ratio?
CORTEXYME INC (CRTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.97).